A phase II study of everolimus in patients with advanced solid malignancies with TSC1, TSC2, NF1, NF2 or STK11 mutations

Keyphrases

• Phase II Study 100%
• Everolimus 100%
• NF2 Gene 100%
• NF1 mutation 100%
• TSC1 mutation 100%
• Advanced Solid Malignancies 100%
• TSC2 mutation 100%
• STK11 Gene 100%
• TSC1 42%
• NF-2 28%
• Tuberous Sclerosis Complex 28%
• Overall Response Rate 28%
• Lung Adenocarcinoma 28%
• NF1 Gene 28%
• Complete Response 28%
• Stable Disease 28%
• TSC1 Gene 28%
• TSC2 Gene 28%
• STK11 28%
• Hyperglycemia 14%
• Tumor 14%
• Disease Progression 14%
• Adverse Events 14%
• Anemia 14%
• Dysregulation 14%
• Initial Dose 14%
• Standard of Care 14%
• Neutrophil Count 14%
• Malignancy 14%
• Single Institution 14%
• 2-cycles 14%
• Systemic Therapy 14%
• Potential Activity 14%
• Lymphocyte Count 14%
• Pericardial Effusion 14%
• Once-daily 14%
• Combination Therapy 14%
• Solid Malignancies 14%
• MTOR Inhibitor 14%
• Clinical Activity 14%
• Metagenomic Next-generation Sequencing (mNGS) 14%
• Treatment-related 14%
• Advanced Solid Tumors 14%
• Single-arm Study 14%
• MTOR Pathway 14%
• Basket Study 14%
• Peripheral Edema 14%
• Confirmed Diagnosis 14%
• Rate Threshold 14%

Medicine and Dentistry

• Cancer 100%
• Everolimus 100%
• Arm 28%
• Lung Adenocarcinoma 28%
• Diseases 28%
• Neoplasm 14%
• Adverse Event 14%
• Anemia 14%
• Disease Exacerbation 14%
• Combination Therapy 14%
• Hyperglycemia 14%
• Solid Malignant Neoplasm 14%
• Next Generation Sequencing 14%
• Systemic Therapy 14%
• Pericardial Fluid 14%
• Mammalian Target of Rapamycin Inhibitor 14%
• Mammalian Target of Rapamycin 14%
• Peripheral Edema 14%
• Lymphocyte 14%
• Neutrophil 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Everolimus 100%
• Lung Adenocarcinoma 28%
• Diseases 28%
• Hyperglycemia 14%
• Neoplasm 14%
• Combination Therapy 14%
• Anemia 14%
• Adverse Event 14%
• Solid Malignant Neoplasm 14%
• Disease Exacerbation 14%
• Mammalian Target of Rapamycin Inhibitor 14%
• Peripheral Edema 14%
• Pericardial Effusion 14%